CU20200087A7 - Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer - Google Patents

Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Info

Publication number
CU20200087A7
CU20200087A7 CU2020000087A CU20200087A CU20200087A7 CU 20200087 A7 CU20200087 A7 CU 20200087A7 CU 2020000087 A CU2020000087 A CU 2020000087A CU 20200087 A CU20200087 A CU 20200087A CU 20200087 A7 CU20200087 A7 CU 20200087A7
Authority
CU
Cuba
Prior art keywords
sub
alkylenyl
alkyl
multitarget
alzheimer
Prior art date
Application number
CU2020000087A
Other languages
English (en)
Other versions
CU24720B1 (es
Inventor
Cordova Adriana Águila
Martínez Alberto Bencomo
Antela Kathleen Castro-Palomino
Llanos Majel Cervantes
García Orestes De Jesús Díaz
Brown Miriam Doreste
Pupo Laura García
Mesa Leonora González
Chaviano Samila León
Soto Del Valle Roberto Menéndez
Tamayo Laura Otaño
Rol Giselle Pentón
Perera Rafaela Perez
Marrero Suchitil Rivera
Chryslaine Rodríguez-Tanty
Carrazana Marquiza Sablón
Original Assignee
Centro De Neurociencias De Cuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Neurociencias De Cuba filed Critical Centro De Neurociencias De Cuba
Priority to CU2020000087A priority Critical patent/CU24720B1/es
Priority to PCT/CU2021/050012 priority patent/WO2022111742A1/es
Priority to CA3200071A priority patent/CA3200071A1/en
Priority to CN202180091389.3A priority patent/CN116829137A/zh
Priority to AU2021388673A priority patent/AU2021388673A1/en
Priority to MX2023006072A priority patent/MX2023006072A/es
Priority to EP21848149.7A priority patent/EP4252749A1/en
Priority to KR1020237020732A priority patent/KR20230118112A/ko
Priority to US18/038,494 priority patent/US20240299334A1/en
Priority to JP2023531700A priority patent/JP2023551249A/ja
Publication of CU20200087A7 publication Critical patent/CU20200087A7/es
Publication of CU24720B1 publication Critical patent/CU24720B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>Esta invención se relaciona con Ia Química Farmacéutica y se refiere a Ia composición farmacéutica de los compuestos de Fórmula I, los cuales muestran acción multiblanco sobre los sistemas colinérgico, glutamatérgico y mitocondrial que se afectan en Ia Enfermedad de Alzheimer (EA). La formulación de estos compuestos incrementa Ia eficacia y tolerancia mediante su administración por vía oral, sublingual, parenteral, transdérmica y nasal.</p> <p>ESPACIO PARA FÓRMULA</p> <p>donde:<br /> R<sub>1</sub>: -alquilenil-C(O)NH-alquilenil- R<sub>3</sub>, -alquilenil-C(O)O-R<sub>4</sub>;<br /> R<sub>3</sub>: -COOH, -OH, -SH, -NH<sub>2</sub>, -NH-alquilo-, -NH-alquilenil-NH<sub>2</sub>, -NH-alquilenil-NH-<br /> C(O)-alquilenil-S-R<sub>5</sub>, -NH-ditiocarbamato-alquilo, -N-alquilo-ditiocarbamato sales metálicas alcalinotérreas; o sales de los grupos arriba mencionados, farmacéuticamente aceptables.<br /> R<sub>4</sub>: grupo succinimidilo;<br /> R<sub>5</sub>: -H, -C(O)-alquilo, -C(O)-C<sub>6</sub>H<sub>5</sub>; y<br /> R<sub>2</sub>: -H,-alquilo.<br /> El término "alquilo" se caracteriza por ser una cadena alifática lineal o ramificada, de átomos de carbono saturados y átomos de hidrógeno, preferentemente metilo o etilo. El término alquilenil se refiere a un análogo divalente de un grupo alquilo lineal o ramificado, preferentemente metilenil (-CH<sub>2</sub>-), etilenil (-CH<sub>2</sub>CH<sub>2</sub>-) o propilenil (-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-).</p> <p> </p> <p><br /> </p> <p> </p> <p> </p>
CU2020000087A 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer CU24720B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2020000087A CU24720B1 (es) 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
PCT/CU2021/050012 WO2022111742A1 (es) 2020-11-24 2021-11-18 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CA3200071A CA3200071A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
CN202180091389.3A CN116829137A (zh) 2020-11-24 2021-11-18 用于治疗阿尔茨海默氏病的作为多靶标治疗剂的萘衍生物的药物组合物
AU2021388673A AU2021388673A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
MX2023006072A MX2023006072A (es) 2020-11-24 2021-11-18 Composicion farmaceutica de derivados de naftaleno como agentes terapeuticos multiblancos para el tratamiento de la enfermedad de alzheimer.
EP21848149.7A EP4252749A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease
KR1020237020732A KR20230118112A (ko) 2020-11-24 2021-11-18 알츠하이머병의 치료를 위한 다중 표적 치료제로서 나프탈렌 유도체의 약학적 조성물
US18/038,494 US20240299334A1 (en) 2020-11-24 2021-11-18 Pharmaceutical composition of naphthalene derivatives as multi-targeted therapeutic agents for the treatment of alzheimer's disease
JP2023531700A JP2023551249A (ja) 2020-11-24 2021-11-18 アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000087A CU24720B1 (es) 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Publications (2)

Publication Number Publication Date
CU20200087A7 true CU20200087A7 (es) 2022-07-08
CU24720B1 CU24720B1 (es) 2024-10-09

Family

ID=80034851

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000087A CU24720B1 (es) 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Country Status (10)

Country Link
US (1) US20240299334A1 (es)
EP (1) EP4252749A1 (es)
JP (1) JP2023551249A (es)
KR (1) KR20230118112A (es)
CN (1) CN116829137A (es)
AU (1) AU2021388673A1 (es)
CA (1) CA3200071A1 (es)
CU (1) CU24720B1 (es)
MX (1) MX2023006072A (es)
WO (1) WO2022111742A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
CN1621039A (zh) 2003-11-25 2005-06-01 上海医药工业研究院 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US8039009B2 (en) 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2007002497A1 (en) 2005-06-23 2007-01-04 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CU24583B1 (es) * 2018-11-06 2022-02-04 Centro De Neurociencias De Cuba Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Also Published As

Publication number Publication date
CN116829137A (zh) 2023-09-29
CA3200071A1 (en) 2022-06-02
EP4252749A1 (en) 2023-10-04
WO2022111742A1 (es) 2022-06-02
MX2023006072A (es) 2023-06-29
US20240299334A1 (en) 2024-09-12
CU24720B1 (es) 2024-10-09
JP2023551249A (ja) 2023-12-07
KR20230118112A (ko) 2023-08-10
AU2021388673A1 (en) 2024-03-28
WO2022111742A4 (es) 2022-11-03

Similar Documents

Publication Publication Date Title
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
CL2023000167A1 (es) Péptidos funcionalizados como agentes antivirales
UY39372A (es) Compuestos antivirales que contienen nitrilo
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
ECSP034562A (es) Agonista del receptor b3-adrenergico y usos de los mismos
AR070810A1 (es) Derivados de 1- bencil-3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 cx3cr1 y p40
SV1999000148A (es) Desnaturalizantes para las sales aminas simpaticomimeticas
AR127050A1 (es) Compuestos espirocíclicos
AR124868A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
CU20200087A7 (es) Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CO2025004988A2 (es) Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
PE20250457A1 (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
PE20250419A1 (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
CR20240362A (es) Compuestos heterocíclicos y métodos de uso
DOP2025000116A (es) Inhibidores de proteasas para tratar o prevenir la infección por coronavirus
AR026856A1 (es) Compuestos agonistas de 5-ht1f y sales faramceuticamente aceptables de los mismos; composiciones farmaceuticas formuladas con dichos compuestos yprocedimiento para inhibir la extravasacion de proteinas neuronales en mamiferos
CR20230458A (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B